Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. The company's drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging two technologies that power a pipeline of high value therapeutics - a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
07/23/24 | $165,000,000 | Series A |
AbbVie Ventures abrdn BVF Partners Cormorant Asset Management ![]() Foresite Capital Freepoint Capital Group Goldman Sachs Hillhouse Investment ![]() Janus Henderson Investors Logos Capital Marshall Wace Omega Funds T. Rowe Price Associates Vida Ventures ![]() | undisclosed |